Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses.

Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu EF, Engreitz JM, Williams RT, Rakhra K, Zhang MH, Rothschilds AM, Kumari S, Kelly RL, Kwan BH, Abraham W, Hu K, Mehta NK, Kauke MJ, Suh H, Cochran JR, Lauffenburger DA, Wittrup KD, Irvine DJ.

Nat Med. 2016 Dec;22(12):1402-1410. doi: 10.1038/nm.4200. Epub 2016 Oct 24.

2.

Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.

Zhou G, Sprengers D, Boor PPC, Doukas M, Schutz H, Mancham S, Pedroza-Gonzalez A, Polak WG, de Jonge J, Gaspersz M, Dong H, Thielemans K, Pan Q, IJzermans JNM, Bruno MJ, Kwekkeboom J.

Gastroenterology. 2017 Oct;153(4):1107-1119.e10. doi: 10.1053/j.gastro.2017.06.017. Epub 2017 Jun 23.

PMID:
28648905
4.

Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.

Liu B, Guo H, Xu J, Qin T, Guo Q, Gu N, Zhang D, Qian W, Dai J, Hou S, Wang H, Guo Y.

MAbs. 2018 Feb/Mar;10(2):315-324. doi: 10.1080/19420862.2017.1409319. Epub 2017 Dec 20.

5.

Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.

Foy SP, Mandl SJ, dela Cruz T, Cote JJ, Gordon EJ, Trent E, Delcayre A, Breitmeyer J, Franzusoff A, Rountree RB.

Cancer Immunol Immunother. 2016 May;65(5):537-49. doi: 10.1007/s00262-016-1816-7. Epub 2016 Mar 10.

6.

RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade.

Ganesh S, Shui X, Craig KP, Park J, Wang W, Brown BD, Abrams MT.

Mol Ther. 2018 Nov 7;26(11):2567-2579. doi: 10.1016/j.ymthe.2018.09.005. Epub 2018 Sep 13.

7.

The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment.

Pennock GK, Chow LQ.

Oncologist. 2015 Jul;20(7):812-22. doi: 10.1634/theoncologist.2014-0422. Epub 2015 Jun 11. Review.

8.

Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.

Philips GK, Atkins M.

Int Immunol. 2015 Jan;27(1):39-46. doi: 10.1093/intimm/dxu095. Epub 2014 Oct 16. Review.

PMID:
25323844
9.

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF.

Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Review.

10.

Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.

Kohlmeyer J, Cron M, Landsberg J, Bald T, Renn M, Mikus S, Bondong S, Wikasari D, Gaffal E, Hartmann G, Tüting T.

Cancer Res. 2009 Aug 1;69(15):6265-74. doi: 10.1158/0008-5472.CAN-09-0579. Epub 2009 Jul 21.

11.

Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.

Kuehm LM, Wolf K, Zahour J, DiPaolo RJ, Teague RM.

Cancer Immunol Immunother. 2019 Jul;68(7):1095-1106. doi: 10.1007/s00262-019-02346-4. Epub 2019 May 18.

PMID:
31104075
12.

SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.

Xue W, Brentville VA, Symonds P, Cook KW, Yagita H, Metheringham RL, Durrant LG.

Oncotarget. 2016 Dec 13;7(50):83088-83100. doi: 10.18632/oncotarget.13070.

13.

PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.

Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, Wamwea A, Bigelow E, Lutz E, Liu L, Yao S, Anders RA, Laheru D, Wolfgang CL, Edil BH, Schulick RD, Jaffee EM, Zheng L.

J Immunother. 2015 Jan;38(1):1-11. doi: 10.1097/CJI.0000000000000062.

14.

Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G.

Cancer Res. 2013 Jun 15;73(12):3591-603. doi: 10.1158/0008-5472.CAN-12-4100. Epub 2013 Apr 30.

15.

T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model.

Liu H, Weber A, Morse J, Kodumudi K, Scott E, Mullinax J, Sarnaik AA, Pilon-Thomas S.

PLoS One. 2018 Apr 25;13(4):e0196033. doi: 10.1371/journal.pone.0196033. eCollection 2018.

16.

Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy.

Moskalenko M, Pan M, Fu Y, de Moll EH, Hashimoto D, Mortha A, Leboeuf M, Jayaraman P, Bernardo S, Sikora AG, Wolchok J, Bhardwaj N, Merad M, Saenger Y.

Cancer Immunol Res. 2015 Mar;3(3):296-304. doi: 10.1158/2326-6066.CIR-14-0120. Epub 2015 Jan 19.

17.

Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.

Huffaker TB, Lee SH, Tang WW, Wallace JA, Alexander M, Runtsch MC, Larsen DK, Thompson J, Ramstead AG, Voth WP, Hu R, Round JL, Williams MA, O'Connell RM.

J Biol Chem. 2017 Nov 10;292(45):18530-18541. doi: 10.1074/jbc.M117.808121. Epub 2017 Sep 14.

18.

Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade.

Ho WS, Wang H, Maggio D, Kovach JS, Zhang Q, Song Q, Marincola FM, Heiss JD, Gilbert MR, Lu R, Zhuang Z.

Nat Commun. 2018 May 29;9(1):2126. doi: 10.1038/s41467-018-04425-z.

19.

Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen.

Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, Deweese TL, Drake CG.

Cancer Immunol Res. 2015 Apr;3(4):345-55. doi: 10.1158/2326-6066.CIR-14-0196. Epub 2014 Dec 19.

20.

Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.

Messenheimer DJ, Jensen SM, Afentoulis ME, Wegmann KW, Feng Z, Friedman DJ, Gough MJ, Urba WJ, Fox BA.

Clin Cancer Res. 2017 Oct 15;23(20):6165-6177. doi: 10.1158/1078-0432.CCR-16-2677. Epub 2017 Aug 28.

Supplemental Content

Support Center